Larsen FO, et al. - Among chemotherapy-naïve patients (n=45) who developed liver metastases from colorectal cancer, researchers assessed the response rate with intrahepatic oxaliplatin combined with systemic 5-FU +/– cetuximab and the conversion rate from unresectable to resectable liver metastases, median progression-free survival, median overall survival, and toxicity. Findings revealed the feasibility as well as low toxicity of intrahepatic infusion of oxaliplatin in 10 minutes with systemic 5-FU in patients with chemo-naïve colorectal cancer. Also, a high response rate and long median overall survival were evident. The response rate was 82%, and 58% converted from unresectable to resectable liver metastases. The median overall survival was 38.7 months and progression-free survival was 12.9 months.